Hyderabad-based pharma player Laurus Labs has received a licence from the Defence Research & Development Organisation (DRDO) for manufacturing and marketing Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India. The licence to Laurus Labs has been granted by DRDO as part of efforts to make the drug affordable and accessible to patients.
DRDO had recently invited expression of interest (EoI) from other pharma companies for manufacturing this drug and had said it would grant licences to 15 companies on a first-come, first-served basis. Meanwhile, the Council of Scientific & Industrial Research institution Indian Institute of Chemical Technology (CSIR-IICT) has been licencing the know-how for 2-DG synthesis to other companies, including Lee Pharma, Suven Pharma, Anthem Biosciences and Nosch Labs.
Did you know that calendars are not the same everywhere in the world? Different countries…
Jammu and Kashmir etched their name in history by winning the Ranji Trophy 2025-26 in…
Union Minister Sarbananda Sonowal inaugurated three key infrastructure projects on National Waterway-2 (NW-2) along the…
The Indian Air Force (IAF) displayed its combat power during Exercise Vayu Shakti 2026 at…
The Central Bank of the UAE has unveiled what it calls the world’s first sovereign…
India’s forex reserves dropped by $2.11 billion to $723.608 billion which are according to the latest…